AMAG PHARMACEUTICALS, INC. Insider Trading for February 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AMAG PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in AMAG PHARMACEUTICALS, INC. for February 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Option Exercise | A | 23.75 | 65,000 | 1,543,750 | 65,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Grant | A | 0.00 | 55,000 | 0 | 291,646 | 236.6 K to 291.6 K (+23.24 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | HEIDEN WILLIAM K | CEO | Grant | A | 0.00 | 30,000 | 0 | 236,646 | 206.6 K to 236.6 K (+14.52 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Option Exercise | A | 23.75 | 20,000 | 475,000 | 20,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Grant | A | 0.00 | 7,500 | 0 | 37,367 | 29.9 K to 37.4 K (+25.11 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Vittiglio Joseph | SVP, General Counse ... | Grant | A | 0.00 | 7,500 | 0 | 29,867 | 22.4 K to 29.9 K (+33.53 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Option Exercise | A | 23.75 | 30,000 | 712,500 | 30,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Grant | A | 0.00 | 12,000 | 0 | 138,195 | 126.2 K to 138.2 K (+9.51 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | THOMAS FRANK E | President & COO | Grant | A | 0.00 | 12,000 | 0 | 126,195 | 114.2 K to 126.2 K (+10.51 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Option Exercise | A | 23.75 | 25,000 | 593,750 | 25,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Grant | A | 0.00 | 10,000 | 0 | 52,000 | 42 K to 52 K (+23.81 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Grund Nicholas | Chief Commercial Of ... | Grant | A | 0.00 | 10,000 | 0 | 42,000 | 32 K to 42 K (+31.25 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Option Exercise | A | 23.75 | 20,000 | 475,000 | 20,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Grant | A | 0.00 | 7,500 | 0 | 38,668 | 31.2 K to 38.7 K (+24.06 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Krop Julie | SVP Clinical & Regu ... | Grant | A | 0.00 | 7,500 | 0 | 31,168 | 23.7 K to 31.2 K (+31.69 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Option Exercise | A | 23.75 | 20,000 | 475,000 | 20,000 | |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 7,500 | 0 | 35,000 | 27.5 K to 35 K (+27.27 %) |
| Feb 27 2017 | AVM | AMAG PHARMACEUTICA ... | Myles Edward H | Chief Financial Off ... | Grant | A | 0.00 | 7,500 | 0 | 27,500 | 20 K to 27.5 K (+37.50 %) |